

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100957-PIP01-23) and to the deferral

MHRA-100957-PIP01-23-M01

Scope of the Application

Active Substance(s)

DEUCRAVACITINIB

Condition(s)

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis & juvenile idiopathic arthritis)

Pharmaceutical Form(s)

Film-coated tablet Age-appropriate oral solid dosage form

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Bristol-Myers Squibb Pharmaceuticals Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Bristol-Myers Squibb Pharmaceuticals Limited submitted to the licensing authority on 16/09/2025 20:09 BST an application for a Modification

The procedure started on 04/11/2025 10:33 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100957-PIP01-23-M01

Of 12/01/2026 12:31 GMT

On the adopted decision for DEUCRAVACITINIB (MHRA-100957-PIP01-23-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for DEUCRAVACITINIB, Film-coated tablet Age-appropriate oral solid dosage form , ORAL USE .

This decision is addressed to Bristol-Myers Squibb Pharmaceuticals Limited, ARC Uxbridge, Sanderson Road, New Denham, Denham, Buckinghamshire, Greater London, UNITED KINGDOM, UB8 1DH

ANNEX I

1. Waiver

1.1 Condition:

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis) The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 5 years of age Pharmaceutical form(s): Film-coated tablet Age-appropriate oral solid dosage form Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

2.2 Indication(s) targeted by the PIP:

Treatment of juvenile psoriatic arthritis

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 5 years to less than 18 years of age

2.4 Pharmaceutical Form(s):

Film-coated tablet Age-appropriate oral solid dosage form

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 4 Population pharmacokinetic (PPK) model to support dose-finding of deucravacitinib in children from 5 years to less than 18 years of age with juvenile psoriatic arthritis (JPsA).
Non-Clinical Studies	0	Not applicable.
Clinical Studies	0	Not applicable.
Extrapolation, Modeling & Simulation Studies	1	Study 1 Development of age-appropriate formulation for paediatric use.
Other Studies	1	Study 2 (DN18003) Definitive juvenile toxicity study in rats.
Other Measures	1	Study 3 (IM011-1071) Double-blind, randomised, placebo-controlled withdrawal study to evaluate pharmacokinetics, safety and efficacy of deucravacitinib in children from 5 years to less than 18 years of age with juvenile psoriatic arthritis (JPsA).

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/08/2030

Deferral of one or more studies contained in the paediatric investigation plan:	Yes
--	-----